About the study
GHB harms are increasing in Australia, with a significant increase in people coming to the emergency department with GHB toxicity. However, no research has sought to understand how, why and where people who identify as heterosexual and cisgender or transgender use GHB. We are hoping you can help shed some light.
The GHB Cultures, Experiences and Practices Study is the first Australian study to specifically examine GHB use among heterosexual and cisgender or transgender people. This study will explore the varied ways that people use GHB, the benefits and harms associated with GHB use and strategies that heterosexual cisgender or transgender people use to prevent harms.
The knowledge generated by this study will be used to inform the delivery of harm-reduction resources and health and wellbeing programs. The National Centre for Clinical Research on Emerging Drugs are leading this research in partnership with researchers from the St Vincent’s Hospital Sydney, University of New South Wales, The University of Sydney and La Trobe University.
This study has been approved by the St Vincent’s Hospital Sydney Human Research Ethics Committee (REF:2021/ETH11824).